

# MI management novelties



## The greatnetwork. In the world

**Prof. Salvatore Di Somma, MD, PhD**

**Professor of Emergency Medicine**  
**Director Postgraduate School of Emergency Medicine**  
**Sapienza University of Rome Italy**  
**Visiting Scholar Professor University California San Diego USA**  
**Expert Professor University of Lund Malmö Sweden**  
**President GREAT –Network Italy**



**SAPIENZA**  
UNIVERSITÀ DI ROMA



# Fourth Universal Definition of Myocardial Infarction (2018)

Joint ESC/ACC/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction



Fourth Joint ESC/ACC/AHA/WHF Universal Definition of Myocardial Infarction  
European Heart Journal 2019; 40: 237-269 - doi:10.1093/eurheartj/ehy462

## Universal Definition of Myocardial Infarction




### Criteria for Clinical Myocardial Infarction


Clinical definition of myocardial infarction denotes presence of  
acute myocardial injury detected by abnormal cardiac biomarkers  
in the setting of evidence of acute myocardial ischaemia.



# Model for interpreting Myocardial Injury and Myocardial Infarction




# Framework for Type 2 MI considering Context and Mechanisms attributable to Acute Myocardial Ischaemia





## Criteria for Type 3 Myocardial Infarction


→ **Patients who suffer cardiac death, with symptoms suggestive of myocardial ischaemia accompanied by presumed new ischaemic ECG changes or ventricular fibrillation, but die before blood samples for biomarkers can be obtained, or before increases in cardiac biomarkers can be identified or myocardial infarction detected by autopsy examination.**



# Myocardial Infarction Type 4a

**PCI-related MI  $\leq 48$  h after the index procedure is defined by elevation of cardiac troponin values  $>5$  times 99<sup>th</sup> percentile URL. In addition, either**

- New ischaemic ECG changes or
- Imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality consistent with an ischaemic aetiology
- Angiographic findings consistent with a procedural flow-limiting complication such as coronary dissection, occlusion of a major epicardial artery or a side-branch occlusion/ thrombus, disruption of collateral flow or distal embolization



Isolated development of new Q waves meets the criteria if cTn values are elevated and rising but less than the pre-specified thresholds for PCI

If cTn values are not  $>5 \times 99^{\text{th}}$  percentile URL, then the term myocardial injury should be used



## Myocardial Infarction Type 4b

Myocardial infarction related to stent-thrombosis is detected by coronary angiography or autopsy in the setting of myocardial ischaemia and with a rise and/or fall of cardiac troponin values with at least one value >99th percentile URL.


The following temporal categories are suggested:

- Acute, 0–24 h
- Subacute, > 24 h to 30 days
- Late, > 30 days to 1 year
- Very late > 1 year



## Myocardial Infarction Type 4c

➔ **Myocardial infarction related to in-stent restenosis, or restenosis following balloon angioplasty in the infarct territory is detected by coronary angiography in the setting of myocardial ischaemia and with a rise and/or fall of cardiac troponin values with at least one value >99th percentile URL**






## Myocardial Infarction Type 5

**CABG-related MI  $\leq 48$  h after the index procedure is defined by elevation of cardiac troponin values  $>10$  times 99<sup>th</sup> percentile URL. In addition, either**


- new pathological Q waves or
- angiographic documented new graft or new native coronary artery occlusion, or
- imaging evidence of new loss of viable myocardium or new regional wall motion abnormality and in a pattern consistent with an ischaemic aetiology.



Isolated development of new Q waves meets the criteria if cTn values are elevated and rising but less than the pre-specified thresholds for CABG

If cTn values are not  $>10 \times$  99th percentile URL, then the term myocardial injury should be used

# How to assess ST-segment elevation



Arrow 1 indicates the onset of the Q wave. Arrow 2 Indicates the onset of the ST-segment or J-point. The difference between points 1 and 2 denotes the magnitude of the ST-segment elevation



# Electrocardiographic Changes\* suggestive of Acute Myocardial Ischaemia

## ST-elevation

New ST-elevation at the J-point in two contiguous leads with the cut points:  $\geq 1$  mm in all leads other than leads  $V_2$ – $V_3$  where the following cut points apply:  $\geq 2$  mm in men  $\geq 40$  years;  $\geq 2.5$  mm in men  $< 40$  years, or  $\geq 1.5$  mm in women regardless of age.


## ST-depression and T wave changes

New horizontal or down-sloping ST-depression  $\geq 0.5$  mm in two contiguous leads and/or T inversion  $> 1$  mm in two contiguous leads with prominent R wave or R/S ratio  $> 1$ .

\*in absence of left ventricular hypertrophy and bundle branch block

# STEMI MANAGEMENT

Modes of patient presentation, components of ischaemic time and flowchart for reperfusion strategy selection





# 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

# What is new? New key recommendations (1)

## Diagnosis

As an alternative to the ESC 0 h/1 h algorithm, it is recommended to use the ESC 0 h/2 h algorithm with blood sampling at 0 h and 2 h, if an hs-cTn test with a validated 0 h/2 h algorithm is available.

For diagnostic purposes, it is not recommended to routinely measure additional biomarkers such as CK, CK-MB, h-FABP, or copeptin, in addition to hs-cTn.

## Risk stratification

Measuring BNP or NT-proBNP plasma concentrations should be considered to gain prognostic information.

## Antithrombotic treatment

Prasugrel should be considered in preference to ticagrelor for NSTEMI-ACS patients who proceed to PCI.



## What is new? New key recommendations (3)

### Antithrombotic treatment (continued)

→ In patients with AF ( $\text{CHA}_2\text{DS}_2\text{-VASc}$  score  $\geq 1$  in men and  $\geq 2$  in women), after a short period of TAT (up to 1 week from the acute event), DAT is recommended as the default strategy using a NOAC at the recommended dose for stroke prevention and single oral antiplatelet agent (preferably clopidogrel).

Discontinuation of antiplatelet treatment in patients treated with OACs is recommended after 12 months.

DAT with an OAC and either ticagrelor or prasugrel may be considered as an alternative to TAT with an OAC, aspirin, and clopidogrel in patients with a moderate or high risk of stent thrombosis, irrespective of the type of stent used.

# What is new? New key recommendations (4)

## Invasive treatment

An early invasive strategy within 24 h is recommended in patients with any of the following high-risk criteria:

- Diagnosis of NSTEMI
- Dynamic or presumably new contiguous ST/T-segment changes suggesting ongoing ischaemia
- Transient ST-segment elevation
- GRACE risk score >140.

A selective invasive strategy after appropriate ischaemia testing or detection of obstructive coronary artery disease by CCTA is recommended in patients considered at low risk.



## What is new? Major changes in recommendations (3)

| 2015  | 2020   |
|---|--|
| <b>Risk assessment</b>  |  |
| It is recommended to use established risk scores for prognosis estimation.  | GRACE risk score models should be considered for estimating prognosis. |
| <b>Pharmacological treatments</b>   |  |
| Bivalirudin (0.75 mg/kg i.v. bolus, followed by 1.75 mg/kg/h for up to 4 h after the procedure) is recommended as an alternative to UFH plus GP IIb/IIIa inhibitors during PCI. | Bivalirudin may be considered as an alternative to UFH.                |

# What is new? New key recommendations (5)

## Invasive treatment (continued)


Delayed, as opposed to immediate, angiography should be considered in haemodynamically stable patients without ST-segment elevation successfully resuscitated after an out-of-hospital cardiac arrest.

Complete revascularization should be considered in NSTEMI-ACS patients without cardiogenic shock and with multivessel CAD.

Complete revascularization during index PCI may be considered in NSTEMI-ACS patients with multivessel disease.


FFR-guided revascularization of non-culprit NSTEMI-ACS lesions may be used during index PCI.





**Figure 1**  
**Diagnostic algorithm and triage in acute coronary syndrome.**

**Figure 2 Value of high-sensitivity cardiac troponin.**



hs-cTn assays (right) are reported in ng/L and provide identical information as conventional assays (left, reported in µg/L) if the concentration is substantially elevated, e.g. above 100 ng/L. In contrast, only hs-cTn allows a precise differentiation between 'normal' and mildly elevated. Therefore, hs-cTn detects a relevant proportion of patients with previously undetectable cardiac troponin concentrations with the conventional assay who have hs-cTn concentrations above the 99th percentile possibly related to AMI.


??? = unknown due to the inability of the assay to measure in the normal range

\*The limit of detection varies among the different hs-cTn assays between 1 ng/L and 5 ng/L. Similarly, the 99th percentile varies among the different hs-cTn assays, mainly being between 10 ng/L and 20 ng/L.




## Table 1 Clinical implications of high-sensitivity cardiac troponin assays (1)

Compared with standard cardiac troponin assays, hs-cTn assays:

- 
- Have higher NPV for AMI.
  - Reduce the 'troponin-blind' interval leading to earlier detection of AMI.
  - Result in ~4% absolute and ~20% relative increases in the detection of type 1 MI and a corresponding decrease in the diagnosis of unstable angina.
  - Are associated with a 2-fold increase in the detection of type 2 MI.

**Figure 3 (1)**  
0 h/1 h rule-out and rule-in algorithm using high-sensitivity cardiac troponin assays in haemodynamically stable patients presenting with suspected non-ST-segment elevation acute coronary syndrome to the emergency department.



<sup>a</sup>Only applicable if CPO >3 h.

[www.escardio.org/guidelines](http://www.escardio.org/guidelines)

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (European Heart Journal 2020 - doi/10.1093/eurheartj/ehaa575)



**Table 3** Assay specific cut-off levels in ng/l within the 0 h/1 h and 0 h/2 h algorithms (1)

| 0 h/1 h algorithm                       | Very low | Low | No 1h Δ | High | 1h Δ |
|---|----------|-----|---------|------|------|
| hs-cTn T (Elecsys; Roche)               | <5       | <12 | <3      | ≥52  | ≥5   |
| hs-cTn I (Architect; Abbott)            | <4       | <5  | <2      | ≥64  | ≥6   |
| hs-cTn I (Centaur; Siemens)             | <3       | <6  | <3      | ≥120 | ≥12  |
| hs-cTn I (Access; Beckman Coulter)      | <4       | <5  | <4      | ≥50  | ≥15  |
| hs-cTn I (Clarity; Singulex)            | <1       | <2  | <1      | ≥30  | ≥6   |
| hs-cTn I (Vitros; Clinical Diagnostics) | <1       | <2  | <1      | ≥40  | ≥4   |
| hs-cTn I (Pathfast; LSI Medience)       | <3       | <4  | <3      | ≥90  | ≥20  |
| hs-cTn I (TriageTrue; Quidel)           | <4       | <5  | <3      | ≥60  | ≥8   |

These cut-offs apply irrespective of age and renal function. Optimized cut-offs for patients above 75 years of age and patients with renal dysfunction have been evaluated, but not consistently shown to provide better balance between safety and efficacy as compared to these universal cut-offs. The algorithms for additional assays are in development.


hs-cTn = high-sensitivity cardiac troponin; TBD = to be determined.

**Table 3** Assay specific cut-off levels in ng/l within the 0 h/1 h and 0 h/2 h algorithms (2)

| 0 h/2 h algorithm                       | Very low | Low | No 2h Δ | High | 2h Δ |
|---|----------|-----|---------|------|------|
| hs-cTn T (Elecsys; Roche)               | <5       | <14 | <4      | ≥52  | ≥10  |
| hs-cTn I (Architect; Abbott)            | <4       | <6  | <2      | ≥64  | ≥15  |
| hs-cTn I (Centaur; Siemens)             | <3       | <8  | <7      | ≥120 | ≥20  |
| hs-cTn I (Access; Beckman Coulter)      | <4       | <5  | <5      | ≥50  | ≥20  |
| hs-cTn I (Clarity; Singulex)            | <1       | Tbd | Tbd     | ≥30  | Tbd  |
| hs-cTn I (Vitros; Clinical Diagnostics) | <1       | Tbd | Tbd     | ≥40  | Tbd  |
| hs-cTn I (Pathfast; LSI Medience)       | <3       | Tbd | Tbd     | ≥90  | Tbd  |
| hs-cTn I (TriageTrue; Quidel)           | <4       | Tbd | Tbd     | ≥60  | Tbd  |

These cut-offs apply irrespective of age and renal function. Optimized cut-offs for patients above 75 years of age and patients with renal dysfunction have been evaluated, but not consistently shown to provide better balance between safety and efficacy as compared to these universal cut-offs. The algorithms for additional assays are in development.

hs-cTn = high-sensitivity cardiac troponin; TBD = to be determined.



**Figure 4 (1) Timing of the blood draws and clinical decisions when using the European Society of Cardiology 0 h/1 h algorithm.**



# COVID-19 Pandemic Leads to Decrease in Emergency Department Wait Times



Public health and medical officials have been trying to reduce wait times in emergency departments (EDs) for years. Surprisingly, the coronavirus disease 2019 (COVID-19) pandemic seems to have done just that.


During the month of April 2020 , **ED visits across the country declined** a staggering [42% from the same time in 2019](#)

Unfortunately, ED visits **for actual medical emergencies are declining as well**. Independent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, emergency calls for [cardiac arrests increased dramatically](#)

in March and many patients were declared dead at the scene.

**JAMA Forum COVID-19** September 17,  
2020

## Surfing the Waves of the COVID-19 Pandemic as a Cardiovascular Clinician



# Thank you From Rome Emergency Medicine Research Group



**SAPIENZA**  
UNIVERSITÀ DI ROMA

